
    
      This is a randomized, double blind, placebo controlled, Phase 2, proof of concept study in
      hospitalized patients with mild to moderate pneumonia due to COVID 19. Written informed
      consent must be obtained from all patients during screening. Following completion of all
      screening assessments and meeting of eligibility criteria, patients will either receive
      antroquinonol or placebo for 14 days in combination with SoC therapy per local SoC policies.
    
  